JP2020510043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510043A5 JP2020510043A5 JP2019549420A JP2019549420A JP2020510043A5 JP 2020510043 A5 JP2020510043 A5 JP 2020510043A5 JP 2019549420 A JP2019549420 A JP 2019549420A JP 2019549420 A JP2019549420 A JP 2019549420A JP 2020510043 A5 JP2020510043 A5 JP 2020510043A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- receptor antagonist
- pharmaceutically acceptable
- acceptable salt
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002464 receptor antagonist Substances 0.000 claims 31
- 229940044551 receptor antagonist Drugs 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 18
- 238000004519 manufacturing process Methods 0.000 claims 14
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 238000007920 subcutaneous administration Methods 0.000 claims 9
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- -1 (R) -2 - {[6 - ((S) -3- methoxy - pyrrolidin-1-yl) -2-phenyl - pyrimidin-4-carbonyl] - amino } -3-phosphono - propionyl Chemical group 0.000 claims 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims 3
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 3
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims 3
- FYXHWMQPCJOJCH-GMAHTHKFSA-N selatogrel Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 FYXHWMQPCJOJCH-GMAHTHKFSA-N 0.000 claims 3
- 201000004569 Blindness Diseases 0.000 claims 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010001902 amaurosis Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- AILAQOYFPLQIFN-UHFFFAOYSA-N butyl piperazine-1-carboxylate Chemical compound CCCCOC(=O)N1CCNCC1 AILAQOYFPLQIFN-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023008155A JP7902762B2 (ja) | 2017-03-15 | 2023-01-23 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
| JP2024230902A JP7906844B2 (ja) | 2017-03-15 | 2024-12-26 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017056175 | 2017-03-15 | ||
| EPPCT/EP2017/056175 | 2017-03-15 | ||
| PCT/EP2018/056372 WO2018167139A1 (en) | 2017-03-15 | 2018-03-14 | Subcutaneous administration of a p2y12 receptor antagonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008155A Division JP7902762B2 (ja) | 2017-03-15 | 2023-01-23 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510043A JP2020510043A (ja) | 2020-04-02 |
| JP2020510043A5 true JP2020510043A5 (enExample) | 2021-04-22 |
| JP7580918B2 JP7580918B2 (ja) | 2024-11-12 |
Family
ID=61899166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549420A Active JP7580918B2 (ja) | 2017-03-15 | 2018-03-14 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
| JP2023008155A Active JP7902762B2 (ja) | 2017-03-15 | 2023-01-23 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008155A Active JP7902762B2 (ja) | 2017-03-15 | 2023-01-23 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11179390B2 (enExample) |
| EP (1) | EP3595666A1 (enExample) |
| JP (2) | JP7580918B2 (enExample) |
| KR (1) | KR102510832B1 (enExample) |
| CN (1) | CN110381947A (enExample) |
| AU (1) | AU2018234056B2 (enExample) |
| BR (1) | BR112019014567A2 (enExample) |
| CL (1) | CL2019002318A1 (enExample) |
| EA (1) | EA201992123A1 (enExample) |
| IL (1) | IL269286B2 (enExample) |
| MA (1) | MA49887A (enExample) |
| MX (1) | MX393334B (enExample) |
| MY (1) | MY205605A (enExample) |
| PH (1) | PH12019502111A1 (enExample) |
| SG (1) | SG11201908128YA (enExample) |
| TW (1) | TWI765002B (enExample) |
| UA (1) | UA125531C2 (enExample) |
| WO (1) | WO2018167139A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109715639B (zh) | 2016-09-22 | 2022-04-19 | 爱杜西亚药品有限公司 | 结晶形式 |
| TWI905227B (zh) * | 2020-07-15 | 2025-11-21 | 新加坡商暉致亞太私人有限公司 | 包含p2y12受體拮抗劑的水性醫藥組合物 |
| CA3223733A1 (en) | 2021-07-13 | 2023-01-19 | Nicole Blumer | A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester |
| CN118871446A (zh) | 2022-03-14 | 2024-10-29 | 晖致亚太私人有限公司 | (r)-2-((叔丁氧基羰基)氨基)-3-(二乙氧基磷酰基)丙酸或其膦酸酯衍生物的合成方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870035A (en) | 1970-07-17 | 1975-03-11 | Survival Technology | Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms |
| US4004577A (en) | 1972-12-04 | 1977-01-25 | Survival Technology, Inc. | Method of treating heart attack patients prior to the establishment of qualified direct contact personal care |
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| US5078680A (en) | 1984-08-08 | 1992-01-07 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US4795433A (en) | 1985-05-20 | 1989-01-03 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US4658830A (en) | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
| GR861289B (en) | 1985-05-20 | 1986-09-16 | Survival Technology | Injection method and apparatus with electrical blood absorbing stimulation |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| CA2375920A1 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| CN1747732A (zh) | 2002-12-11 | 2006-03-15 | 舍林股份公司 | 作为血小板腺苷二磷酸受体拮抗剂的2－氨基羰基喹啉化合物 |
| WO2004092189A1 (en) | 2003-04-09 | 2004-10-28 | Wyeth | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| WO2005002574A1 (en) | 2003-06-24 | 2005-01-13 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| ES2421448T3 (es) | 2005-10-21 | 2013-09-02 | Actelion Pharmaceuticals Ltd | Derivados de piperazina como agentes contra la malaria |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CA2684644A1 (en) | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| US20090048216A1 (en) | 2007-05-02 | 2009-02-19 | Portola Pharmaceuticals, Inc. | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| RU2483072C2 (ru) | 2007-11-29 | 2013-05-27 | Актелион Фармасьютиклз Лтд | Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12 |
| EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| MX2011010200A (es) | 2009-04-08 | 2011-10-14 | Actelion Pharmaceuticals Ltd | 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp). |
| JP5536876B2 (ja) | 2009-04-22 | 2014-07-02 | アクテリオン ファーマシューティカルズ リミテッド | チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用 |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| EP2585161A1 (en) | 2010-06-23 | 2013-05-01 | Stefan Kralev | Medical device for self-administration of patients with acute coronary events |
| CN109715639B (zh) | 2016-09-22 | 2022-04-19 | 爱杜西亚药品有限公司 | 结晶形式 |
-
2018
- 2018-03-14 SG SG11201908128Y patent/SG11201908128YA/en unknown
- 2018-03-14 US US16/494,254 patent/US11179390B2/en active Active
- 2018-03-14 MY MYPI2019005278A patent/MY205605A/en unknown
- 2018-03-14 EP EP18715499.2A patent/EP3595666A1/en active Pending
- 2018-03-14 JP JP2019549420A patent/JP7580918B2/ja active Active
- 2018-03-14 MA MA049887A patent/MA49887A/fr unknown
- 2018-03-14 TW TW107108546A patent/TWI765002B/zh active
- 2018-03-14 KR KR1020197029753A patent/KR102510832B1/ko active Active
- 2018-03-14 MX MX2019009559A patent/MX393334B/es unknown
- 2018-03-14 UA UAA201910293A patent/UA125531C2/uk unknown
- 2018-03-14 AU AU2018234056A patent/AU2018234056B2/en active Active
- 2018-03-14 WO PCT/EP2018/056372 patent/WO2018167139A1/en not_active Ceased
- 2018-03-14 CN CN201880017104.XA patent/CN110381947A/zh active Pending
- 2018-03-14 BR BR112019014567-2A patent/BR112019014567A2/pt not_active Application Discontinuation
- 2018-03-14 EA EA201992123A patent/EA201992123A1/ru unknown
-
2019
- 2019-08-16 CL CL2019002318A patent/CL2019002318A1/es unknown
- 2019-09-11 IL IL269286A patent/IL269286B2/en unknown
- 2019-09-13 PH PH12019502111A patent/PH12019502111A1/en unknown
-
2023
- 2023-01-23 JP JP2023008155A patent/JP7902762B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002662A5 (enExample) | ||
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| JP2011173928A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| JP2009102342A5 (enExample) | ||
| JP2010526101A5 (enExample) | ||
| FI3577124T3 (fi) | Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon | |
| HRP20221100T1 (hr) | Stabilna parenteralna formulacija nimopidina | |
| JP2014516942A5 (enExample) | ||
| JP2018197248A (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
| EP3528828B1 (en) | Terlipressin composition for use in treating ascites | |
| ES2704229T3 (es) | Agonistas selectivos del receptor AT2 para su uso en el tratamiento de la caquexia | |
| JP2019517542A5 (enExample) | ||
| ES2971959T3 (es) | Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2017533211A5 (enExample) | ||
| KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
| JP2012526099A5 (enExample) | ||
| WO2010110428A1 (ja) | 掻痒の予防及び／または治療剤 | |
| TWI631944B (zh) | 氯硝柳胺及其衍生物的用途 | |
| AR062894A1 (es) | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) | |
| WO2019242688A1 (zh) | 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤 | |
| JP2008526816A5 (enExample) | ||
| JP2016503406A5 (enExample) | ||
| JP2016510738A5 (enExample) |